VRPX
Virpax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 5.8M | 5.8M | 5.1M | 10.8M | 4.8M |
| SG&A Expense | 6.3M | 6.3M | 7.8M | 11.1M | 7.2M |
| General & Admin Expense | 6.3M | 6.3M | 7.8M | 11.1M | 7.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 2.8M | 194.4K | 62.3K |
| Total Operating Expenses | 12.1M | 12.1M | 15.7M | 21.8M | 12.0M |
| Cost and Expenses | 12.1M | 12.1M | 15.7M | 21.8M | 12.0M |
| Operating Income (EBIT) | (12.1M) | (12.1M) | (15.7M) | (21.8M) | (12.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 103.7K | 103.8K | — | — | 92.8K |
| Net Interest Income | (103.8K) | (103.8K) | — | — | (92.7K) |
| Other Non-Op Income/Expense | 12.7K | 12.7K | 500.3K | 194.4K | (30.6K) |
| Non-Operating Income (excl Interest) | (34.4K) | (116.5K) | (500.3K) | (194.4K) | (62.3K) |
| EBT (Pre-Tax Income) | (12.1M) | (12.1M) | (15.2M) | (21.7M) | (12.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.1M) | (12.1M) | (15.2M) | (21.5M) | (12.1M) |
| Earnings from Cont. Ops | (12.1M) | (12.1M) | (15.2M) | (21.7M) | (12.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.1M) | (12.1M) | (15.2M) | (21.7M) | (12.1M) |
| Per Share | |||||
| Basic EPS | ($5.73) | ($70.91) | ($12.97) | ($18.32) | ($10.37) |
| Diluted EPS | ($5.73) | ($70.91) | ($12.97) | ($18.32) | ($10.37) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.3M | 4.3M | 1.2M | 1.2M | 1.2M |
| Diluted Shares Outstanding | 4.3M | 4.3M | 1.2M | 1.2M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (3.4M) | (12.0M) | (2.2M) | (3.3M) | 62.3K |
| D&A | 8.7M | — | 12.9M | 18.3M | 12.0M |
| EBIT | (12.0M) | (12.0M) | (15.2M) | (21.7M) | (12.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2024